PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32818617-0	2020	Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DR2/3 gene expression in the human brain.	naxagolide	89-93	TNF receptor superfamily member 25	Homo sapiens	111-116
33454626-0	2021	Dopamine D2/3 receptor availability in cocaine use disorder individuals with obesity as measured by [11C]PHNO PET.	naxagolide	105-109	dopamine receptor D2	Homo sapiens	0-22
31601695-0	2020	PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes.	naxagolide	75-79	dopamine receptor D2	Homo sapiens	26-53
32201327-0	2020	Separating dopamine D2 and D3 receptor sources of [11C]-(+)-PHNO binding potential: Independent component analysis of competitive binding.	naxagolide	60-64	dopamine receptor D2	Homo sapiens	11-38
32201327-10	2020	In summary, ICA successfully separated D2-and D3-related components of the [11C]-(+)-PHNO binding signal, establishing this approach as a powerful data-driven method to quantify distinct biological features from PET data composed of mixed data sources.	naxagolide	85-89	immunoglobulin heavy diversity 2-15	Homo sapiens	39-48
31601695-3	2020	We previously demonstrated the potential utility of PET imaging with the dopamine D2 and D3 receptor agonist 3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol (11C-(+)-PHNO) to differentiate between healthy control (HC) and T1DM individuals.	naxagolide	169-181	dopamine receptor D2	Homo sapiens	73-100
31645049-10	2020	RESULTS: D2R antagonists thioridazine, pimozide, haloperidol, and remoxipride decrease spheroid formation behaviors at a selective 100 nmol/L concentration, while D2R agonists PHNO, sumanirole, and ropinirole increase the formation of spheroids.	naxagolide	176-180	dopamine receptor D2	Homo sapiens	9-12
31645049-10	2020	RESULTS: D2R antagonists thioridazine, pimozide, haloperidol, and remoxipride decrease spheroid formation behaviors at a selective 100 nmol/L concentration, while D2R agonists PHNO, sumanirole, and ropinirole increase the formation of spheroids.	naxagolide	176-180	dopamine receptor D2	Homo sapiens	163-166
26873034-0	2017	Exploring the relationship between social attachment and dopamine D2/3 receptor availability in the brains of healthy humans using [11C]-(+)-PHNO.	naxagolide	137-145	dopamine receptor D2	Homo sapiens	57-79
31264367-0	2019	Disrupted-in-schizophrenia 1 functional polymorphisms and D2 /D3 receptor availability: A [11 C]-(+)-PHNO imaging study.	naxagolide	101-105	DISC1 scaffold protein	Homo sapiens	0-28
31264367-5	2019	Here, we investigated the relationship between the three most common polymorphisms altering the amino-acid sequence of the DISC1 protein (Ser704Cys (rs821616), Leu607Phe (rs6675281) and Arg264Gln (rs3738401)) and striatal D2/3 R availability in 41 healthy human volunteers, using [11 C]-(+)-PHNO positron emission tomography.	naxagolide	291-295	DISC1 scaffold protein	Homo sapiens	123-128
29883636-13	2018	Knowledge that both D2R and D3R are expressed in the human retina, and potentially quantifiable in vivo using [11C]-(+)-PHNO, poses new research avenues for better understanding the role of retinal dopamine in human vision.	naxagolide	120-124	dopamine receptor D2	Homo sapiens	20-23
28825117-3	2017	METHODS: Binding of [3H]-(+)-PHNO in the rat cerebellum and striatum was used to measure occupancy by buspirone of DRD3 or DRD2, respectively.	naxagolide	25-33	dopamine receptor D3	Rattus norvegicus	115-119
30659274-0	2019	Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans.	naxagolide	94-98	BP1	Homo sapiens	72-75
29442593-12	2018	%CS+, %Cs-, and %Neutral were positively correlated with [11C]-(+)-PHNO binding in the globus pallidus.	naxagolide	67-71	citrate synthase	Homo sapiens	1-3
16088951-0	2005	Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.	naxagolide	48-52	iodothyronine deiodinase 3	Homo sapiens	82-100
22213512-2	2012	We quantified the affinity of [11C]-(+)-PHNO for the D2R and D3R in the living primate brain.	naxagolide	36-44	dopamine receptor D2	Homo sapiens	53-56
22213512-5	2012	The regional binding potential (BP(ND) ) and the corresponding doses of injected (+)-PHNO were used as inputs in a model that quantified the affinity of (+)-PHNO for the D2R and D3R, as well as the regional fractions of the [11C]-(+)-PHNO signal attributable to D3R binding.	naxagolide	153-161	dopamine receptor D2	Homo sapiens	170-173
22213512-5	2012	The regional binding potential (BP(ND) ) and the corresponding doses of injected (+)-PHNO were used as inputs in a model that quantified the affinity of (+)-PHNO for the D2R and D3R, as well as the regional fractions of the [11C]-(+)-PHNO signal attributable to D3R binding.	naxagolide	153-161	dopamine receptor D2	Homo sapiens	170-173
22213512-6	2012	(+)-PHNO in vivo affinity for the D3R (K(d)/f(ND) ~0.23-0.56 nM) was 25- to 48-fold higher than that for the D2R (K(d)/f(ND) ~11-14 nM).	naxagolide	0-8	dopamine receptor D2	Homo sapiens	109-112
19153147-0	2009	Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson"s disease.	naxagolide	64-78	dopamine receptor D3	Homo sapiens	25-45
26718579-0	2016	D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia.	naxagolide	37-41	dopamine receptor D3	Homo sapiens	0-20
26141509-0	2015	Imaging the D3 dopamine receptor across behavioral and drug addictions: Positron emission tomography studies with [(11)C]-(+)-PHNO.	naxagolide	122-130	dopamine receptor D3	Homo sapiens	12-32
26141509-5	2015	A particularly useful tool in investigating this question is the PET imaging probe [(11)C]-(+)-PHNO, which binds to D2/3 dopamine receptors but has preferential affinity for D3.	naxagolide	91-99	dopamine receptor D2	Homo sapiens	116-139
24884386-3	2014	RESULTS: Intracerebroventricular (icv) injection of PHNO, a D2R agonist, in the morning inhibited TIDA and midbrain DA neurons" activities, and stimulated PRL secretion.	naxagolide	52-56	prolactin	Rattus norvegicus	155-158
23921256-0	2014	Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO.	naxagolide	161-172	dopamine receptor D3	Homo sapiens	11-31
19084908-0	2009	Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2(High) receptors and marked supersensitivity to the dopamine agonist (+)PHNO.	naxagolide	169-173	glutamate receptor, metabotropic 3	Mus musculus	29-34
16088951-3	2005	The K(i) values for the human cloned D2(High) and D3(High) receptors, respectively, were 19 and 9 nM for pramipexole, 0.24 and 0.6 nM for +PHNO, 0.7 and 1.3 nM for bromocriptine, 0.5 and 2.6 nM for apomorphine, and 0.09 and 0.25 nM for (-)N-propylnorapomorphine.	naxagolide	139-143	iodothyronine deiodinase 3	Homo sapiens	50-68
16088951-5	2005	The D3(High) receptors are less selectively occupied by +PHNO, bromocriptine, apomorphine, and -NPA.	naxagolide	57-61	iodothyronine deiodinase 3	Homo sapiens	4-22
15310196-6	2004	In the following stages, PhNHOH, once formed, is rapidly oxidized by Ru(IV)=O(2+) to PhNO and PhNHNHPh to PhN=NPh.	naxagolide	85-89	carbamoyl-phosphate synthase 1	Homo sapiens	25-28
15310196-8	2004	In the final stages of the six-electron reactions, PhNO is oxidized to PhNO(2) and PhN=NPh to PhN(O)=NPh.	naxagolide	51-55	carbamoyl-phosphate synthase 1	Homo sapiens	71-74
15310196-8	2004	In the final stages of the six-electron reactions, PhNO is oxidized to PhNO(2) and PhN=NPh to PhN(O)=NPh.	naxagolide	71-75	carbamoyl-phosphate synthase 1	Homo sapiens	51-54
9292626-6	1997	Olanzapine did produce full clozapine-lever responding following pretreatment with the dopamine D2-receptor agonist (+)-PHNO (0.003-0.01 mg/kg).	naxagolide	116-124	dopamine receptor D2	Homo sapiens	87-107
35545150-0	2022	Interaction of the preferential D3 agonist (+)PHNO with dopamine D3-D2 receptor heterodimers and diverse classes of monoamine receptor: relevance for PET imaging.	naxagolide	46-50	iodothyronine deiodinase 3	Homo sapiens	65-67
1924492-3	1991	D-2 agonists protected mice against pilocarpine-induced seizures in the rank order of potency PHNO greater than pergolide greater than greater than lisuride = LY 171555 much greater than RU 24213, with ED50 values ranging from 0.17 mg/kg for PHNO to greater than 4.5 mg/kg for RU 24213.	naxagolide	94-98	solute carrier family 3 member 1	Rattus norvegicus	0-3
1924492-3	1991	D-2 agonists protected mice against pilocarpine-induced seizures in the rank order of potency PHNO greater than pergolide greater than greater than lisuride = LY 171555 much greater than RU 24213, with ED50 values ranging from 0.17 mg/kg for PHNO to greater than 4.5 mg/kg for RU 24213.	naxagolide	242-246	solute carrier family 3 member 1	Rattus norvegicus	0-3
1982893-1	1990	Brain microdialysis was used to localize the mechanism of action of the effect induced by the D-2 agonists (-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin [(-)-N-0437] and (+)-4-propyl-9-hydroxynaphtoxazine [(+)-PHNO], on the release of DA in the striatum.	naxagolide	217-225	solute carrier family 3 member 1	Rattus norvegicus	94-97
1981508-5	1990	Liver microsomes from control rats metabolized DZ at a rate of 0.86 nmol/nmol cytochrome P-450/min.	naxagolide	47-49	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	78-98
34349232-10	2021	There was a positive association between (11C)-(+)-PHNO binding in the SN (almost exclusively reflective of DRD3) and alpha (lower values reflect higher alcohol demand) in the APT after Bonferroni corrections (r = 0.66, p = 0.0080).	naxagolide	51-55	dopamine receptor D3	Homo sapiens	108-112
35545150-8	2022	In conclusion, (+)PHNO is a potent agonist at hD4.4, h5-HT1A and h5-HT7 as well as hD3 and hD2L receptors, and it potently activates dopamine hD3-hD2L heterodimers.	naxagolide	18-22	iodothyronine deiodinase 3	Homo sapiens	142-145
35545150-1	2022	(+)-4-Propyl-9-hydroxynaphthoxazine ((+)PHNO) is a high affinity, preferential dopamine D3 versus D2 agonist employed in view of its high specificity and excellent signal-to-noise ratio as a radiotracer for positron emission tomography (PET) imaging.	naxagolide	40-44	iodothyronine deiodinase 3	Homo sapiens	88-90
35545150-3	2022	In addition to hD3 and hD2L receptors, (+)PHNO revealed high affinity at hD4.4 but not hD1 or hD5 receptors.	naxagolide	42-46	Rho GDP dissociation inhibitor beta	Homo sapiens	73-76
35545150-6	2022	In binding assays with membranes derived from cells co-expressing hD3 and hD2L receptors and labeled with (3H)Nemonapride or (3H)Spiperone, the proportion of high affinity binding sites recognized by (+)PHNO was higher than an equivalent mixture of membranes from cells expressing hD3or hD2L receptors, suggesting that (+)PHNO promotes formation of hD3-hD2L heterodimers.	naxagolide	203-207	iodothyronine deiodinase 3	Homo sapiens	66-69
35545150-6	2022	In binding assays with membranes derived from cells co-expressing hD3 and hD2L receptors and labeled with (3H)Nemonapride or (3H)Spiperone, the proportion of high affinity binding sites recognized by (+)PHNO was higher than an equivalent mixture of membranes from cells expressing hD3or hD2L receptors, suggesting that (+)PHNO promotes formation of hD3-hD2L heterodimers.	naxagolide	203-207	iodothyronine deiodinase 3	Homo sapiens	281-284
35545150-6	2022	In binding assays with membranes derived from cells co-expressing hD3 and hD2L receptors and labeled with (3H)Nemonapride or (3H)Spiperone, the proportion of high affinity binding sites recognized by (+)PHNO was higher than an equivalent mixture of membranes from cells expressing hD3or hD2L receptors, suggesting that (+)PHNO promotes formation of hD3-hD2L heterodimers.	naxagolide	203-207	iodothyronine deiodinase 3	Homo sapiens	349-352
35545150-7	2022	Further, in cells co-expressing hD3 and hD2L receptors, (+)PHNO showed higher efficacy for inhibiting forskolin stimulated adenylyl cyclase and inducing adenylyl cyclase super-sensitization than in cells transfected with only hD2L receptors.	naxagolide	59-63	iodothyronine deiodinase 3	Homo sapiens	32-35
35545150-8	2022	In conclusion, (+)PHNO is a potent agonist at hD4.4, h5-HT1A and h5-HT7 as well as hD3 and hD2L receptors, and it potently activates dopamine hD3-hD2L heterodimers.	naxagolide	18-22	Rho GDP dissociation inhibitor beta	Homo sapiens	46-49
35545150-8	2022	In conclusion, (+)PHNO is a potent agonist at hD4.4, h5-HT1A and h5-HT7 as well as hD3 and hD2L receptors, and it potently activates dopamine hD3-hD2L heterodimers.	naxagolide	18-22	iodothyronine deiodinase 3	Homo sapiens	83-86
2901697-1	1988	PHNO [(+)-4-propyl-9-hydroxynaphthoxazine] is a chemically novel and highly potent dopamine (D2) receptor agonist without D1 activity.	naxagolide	0-4	dopamine receptor D2	Homo sapiens	83-105
2547181-3	1989	Inhibitory effects of 0.5 nM PHNO on prolactin release and cAMP generation were abolished by coincubation with 10 nM haloperidol, a D2 dopamine receptor antagonist.	naxagolide	29-33	dopamine receptor D2	Rattus norvegicus	132-152
2547181-5	1989	Thus, PHNO appears to activate the D2 dopamine receptor to inhibit the formation of cAMP and the secretion of prolactin.	naxagolide	6-10	dopamine receptor D2	Rattus norvegicus	35-55
2563751-6	1989	Pretreatment with centrally acting dopamine antagonists (spiperone or haloperidol) prevented the (+)-PHNO-induced changes in serum corticosterone, prolactin and brain catecholamines.	naxagolide	97-105	prolactin	Rattus norvegicus	147-156
3720849-7	1986	In models for postsynaptic DA receptor stimulation (induction of stereotypy in rats, reversal of reserpine-induced immobility of mice) N-0500 was found to be as effective as RU-29717 in inducing stereotyped behaviors in rats, but was much less effective than RU-29717 in restoring the mobility of reserpinized mice, suggesting a selectivity for D-2 DA receptors by N-0500 in contrast to the mixed D-1/D-2 receptor activity of RU-29717.	naxagolide	135-141	dopamine receptor D2	Mus musculus	401-413
3720849-10	1986	On the basis of its very potent in vivo central D-2 dopamine receptor activities and its in vitro selectivity, N-0500, being the most potent compound within the series, is a much more specifically acting drug than many of the dopaminergic ergolines and might therefore be a good candidate for the treatment of Parkinson"s disease.	naxagolide	111-117	dopamine receptor D2	Mus musculus	48-69
2907097-8	1988	These results confirm the efficacy of PHNO as an anti-parkinsonian drug and link the production of dyskinesia with the D-2 dopamine receptor.	naxagolide	38-42	dopamine receptor D2	Homo sapiens	119-140